Elderd Lands’ passionate belief is that without an active role of Private Equity (PE), the domain of Public Health will not easily be transformed.

Transformation comes with certain levels of financial uncertainty that are typically avoided in the public domain of healthcare. PE however, strives to achieve good return on investments. To obtain a healthy risk reward they invest in companies that innovate and thus change the current paradigms.

Elderd Land will share some of his key learnings with INSEAD alumni and will take questions from participants. The session will be held in the English language.

About Elderd Land

Elderd Land joined Gimv in 2000, investing in the Health & Care and Technology sectors. He is an engaged board member and sparring partner for the entrepreneurs with focus on business building and value creation in the portfolio companies. He holds board seats in various companies. Previously he managed the investments in a.o. Equipe Zorgbedrijven (sold to Nordic Capital), Oldelft Ultrasound (sold to Smile Invest), 3mensio Medical Imaging (acquired by Esaote), GreenPeak (acquired by Qorvo), Liquavista (acquired by Samsung), and actively supported other Gimv investments such as Telenet (Euronext) and Option (Euronext). Prior to joining Gimv, Elderd worked at ABN AMRO Corporate Finance as head of the telecom sector team in Amsterdam, and at KPN Telecom in the International Business Development group. In both roles, he was involved in a wide range of M&A transactions in Europe and Asia. Elderd holds a Master in Business Administration from the Erasmus University of Rotterdam (the Netherlands).

About Thomas Calis

Thomas Calis is chair of the Dutch INSEAD Healthcare & Lifesciences club. He has a passion for learning development and leadership. He is active as a mentor for YES!Delft. In his professional life he is Managing Director of Eurocept Pharmaceuticals / CEO of Lucane Pharma SA.

Looking forward meeting you online.

Isabelle Cochard, Cynthia de Leeuw-Go and Thomas Calis

INSEAD SIG Healthcare & Life Sciences

‘The transformational role of PE in Public Healthcare’, 9 Feb.22